How well does Trogarzo work to treat multidrug-resistant (MDR) HIV-1?
Medically reviewed by Drugs.com. Last updated on Sep 28, 2022.
Trogarzo (ibalizumab-uiyk) was studied in a clinical trial of 40 multidrug-resistant (MDR) HIV-1 infection patients with high HIV virus levels. These patients had already received multiple other HIV treatments (some patients had received 10 or more). Most patients (33 of the 40 patients, or 83%) experienced a significant decrease in their HIV-RNA levels one week after Trogarzo was added to their ineffective antiretroviral regimens. After 24 weeks of Trogarzo plus other antiretroviral drugs, 43% of the trial’s participants achieved HIV RNA suppression.
Related medical questions
- How is Trogarzo used in the treatment of HIV?
- What are the side effects with HIV treatment Trogarzo?
- How do you increase your CD4 count?
- What is an undetectable HIV viral load?
- Can Descovy be used for pre-exposure prophylaxis (PrEP) in HIV?
- Modafinil vs Adderall: What's the difference?
- Who are the actors in the Dovato commercial?
- Which medicines should not be taken with Biktarvy?
- Truvada vs Descovy: How do they compare for HIV and PrEP?
- Does Dovato cause weight gain?
- What if I miss a dose of Biktarvy?